文献速递白血病

FLT3靶向BiTE分子与CAR T细胞在AML中的头对头临床前比较:共刺激信号缓解T细胞耗竭

FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.
PubMed 文献 · Blood Adv · 2026-01-01

该临床前研究对比了FLT3靶向双特异性T细胞衔接分子(BiTE)与第二代FLT3特异性CAR T细胞在急性髓系白血病(AML)中的效果。两者短期杀伤AML细胞系和原代患者细胞效果相当且不损伤健康造血干祖细胞,但长期抗原暴露下CAR T细胞维持更强杀伤和增殖潜力,在异种移植模型中肿瘤控制更优、生存期更长、T细胞浸润更多。骨髓T细胞转录组显示BiTE组耗竭相关基因特征更明显,提供CD86介导的共刺激可增强BiTE重定向T细胞的抗肿瘤活性。

要点

  • FLT3是AML中表达限于健康造血组织的有前景治疗靶点。
  • CAR T细胞较BiTE分子在长期抗原暴露下维持更强杀伤和增殖潜力。
  • CD86共刺激信号可增强BiTE重定向T细胞的体内外抗肿瘤活性。

核心结论

  • FLT3是AML可行且选择性的免疫治疗靶点。
  • CAR T细胞在体内肿瘤控制、生存期和T细胞浸润方面优于FLT3 BiTE分子。
  • CD86介导的共刺激信号可增强BiTE重定向T细胞的抗肿瘤活性。

研究设计与样本

  • 头对头临床前比较FLT3靶向BiTE分子与第二代FLT3特异性CAR T细胞。
  • 体外使用AML细胞系和原代患者来源细胞,并评估健康造血干祖细胞。
  • 体内使用AML异种移植模型,并对骨髓回收T细胞进行转录组分析。

主要发现

  • 两种方法对AML细胞系和原代患者细胞均诱导强细胞毒性,体外不损伤健康造血干祖细胞。
  • 长期抗原暴露后T细胞功能进行性下降和代谢耗竭,但CAR T细胞维持杀伤能力和增殖潜力。
  • 异种移植模型中CAR T细胞较BiTE分子实现更优肿瘤控制、更长生存期和更高T细胞浸润。
  • BiTE分子治疗小鼠的骨髓T细胞呈现独特的耗竭相关基因特征。
  • CD86共刺激可增强BiTE重定向T细胞的体内外抗肿瘤活性。

临床怎么用

  • FLT3可作为AML免疫治疗的选择性靶点。
  • CAR T细胞在持久性和体内疗效上可能优于BiTE分子。
  • 联合共刺激信号可能提升BiTE重定向T细胞疗法的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

T-cell-based immunotherapies have revolutionized treatment paradigms in B-cell malignancies, yet their translation to acute myeloid leukemia (AML) has been hindered by a scarcity of tumor-restricted antigens and the risk of on-target off-leukemia toxicity. FLT3 has emerged as a promising therapeutic target with limited expression in healthy hematopoietic tissues. Here, we performed a head-to-head preclinical comparison of an FMS-like tyrosine kinase 3 (FLT3)-directed bispecific T-cell engager (BiTE) molecule and second-generation FLT3-specific chimeric antigen receptor (CAR) T cells. Both approaches induced potent cytotoxicity against AML cell lines and primary patient-derived cells but spared healthy hematopoietic stem and progenitor cells in vitro. Despite similar short-term efficacy, prolonged antigen exposure demonstrated progressive functional decline and metabolic exhaustion; however, CAR T cells maintained cytotoxic capacity and proliferative potential over time. In AML xenograft models, CAR T cells achieved superior tumor control, prolonged survival, and greater T-cell infiltration than BiTE molecule-treated counterparts. Transcriptomic profiling of T cells recovered from the bone marrow further revealed a distinct exhaustion-associated gene signature in samples from mice that had been treated with the FLT3 BiTE molecule. Importantly, provision of CD86-mediated costimulation enhanced antitumor activity of BiTE-redirected T cells in vitro and in vivo. These findings establish FLT3 as a viable and selective immunotherapeutic target in AML and underscore the functional and transcriptional differences between BiTE molecule-redirected T cells and CAR T cells. Moreover, they reveal a critical role for costimulatory signaling in sustaining the efficacy of T-cell-based therapies in vivo, offering a rationale for improving T cell-redirection strategies in myeloid malignancies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Rohrbacher L, Nixdorf D, Stadler H, et al. FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion. Blood Adv. 2026. PMID: 41324594. doi:10.1182/bloodadvances.2025018168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。